"rationale","uuid:ID","name","instanceType","label","description","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7c020769-1b99-445a-a37d-2ad297b911be","Study Design 1","StudyDesign","","The main design for the study","StudyDesign_1"
